JP2023537131A5 - - Google Patents
Info
- Publication number
- JP2023537131A5 JP2023537131A5 JP2023509663A JP2023509663A JP2023537131A5 JP 2023537131 A5 JP2023537131 A5 JP 2023537131A5 JP 2023509663 A JP2023509663 A JP 2023509663A JP 2023509663 A JP2023509663 A JP 2023509663A JP 2023537131 A5 JP2023537131 A5 JP 2023537131A5
- Authority
- JP
- Japan
- Prior art keywords
- antigen
- cancer
- antibody
- igsf8
- monoclonal antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2026034828A JP2026097939A (ja) | 2020-08-10 | 2026-03-05 | Ｉｇｓｆ８を標的化することによる自己免疫疾患および癌を治療するための組成物および方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2020108129 | 2020-08-10 | ||
| CNPCT/CN2020/108129 | 2020-08-10 | ||
| PCT/CN2021/111469 WO2022033419A2 (en) | 2020-08-10 | 2021-08-09 | Compositions and methods for treating autoimmune diseases and cancers by targeting igsf8 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2026034828A Division JP2026097939A (ja) | 2020-08-10 | 2026-03-05 | Ｉｇｓｆ８を標的化することによる自己免疫疾患および癌を治療するための組成物および方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023537131A JP2023537131A (ja) | 2023-08-30 |
| JP2023537131A5 true JP2023537131A5 (enExample) | 2024-08-16 |
| JP7832177B2 JP7832177B2 (ja) | 2026-03-17 |
Family
ID=77431086
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023509663A Active JP7832177B2 (ja) | 2020-08-10 | 2021-08-09 | Ｉｇｓｆ８を標的化することによる自己免疫疾患および癌を治療するための組成物および方法 |
| JP2024507076A Pending JP2024532726A (ja) | 2020-08-10 | 2022-08-09 | Ｉｇｓｆ８を標的化することによる自己免疫疾患および癌を治療するための組成物および方法 |
| JP2026034828A Pending JP2026097939A (ja) | 2020-08-10 | 2026-03-05 | Ｉｇｓｆ８を標的化することによる自己免疫疾患および癌を治療するための組成物および方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024507076A Pending JP2024532726A (ja) | 2020-08-10 | 2022-08-09 | Ｉｇｓｆ８を標的化することによる自己免疫疾患および癌を治療するための組成物および方法 |
| JP2026034828A Pending JP2026097939A (ja) | 2020-08-10 | 2026-03-05 | Ｉｇｓｆ８を標的化することによる自己免疫疾患および癌を治療するための組成物および方法 |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US20230303695A1 (enExample) |
| EP (2) | EP4192866A2 (enExample) |
| JP (3) | JP7832177B2 (enExample) |
| KR (2) | KR20230077722A (enExample) |
| CN (2) | CN116724051A (enExample) |
| AU (2) | AU2021325225A1 (enExample) |
| CA (2) | CA3188996A1 (enExample) |
| IL (2) | IL300537A (enExample) |
| MX (2) | MX2023001707A (enExample) |
| WO (2) | WO2022033419A2 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7137696B2 (ja) | 2019-05-14 | 2022-09-14 | プロヴェンション・バイオ・インコーポレイテッド | １型糖尿病を予防するための方法および組成物 |
| KR20230092863A (ko) | 2020-06-11 | 2023-06-26 | 프로벤션 바이오, 인코포레이티드 | 제1형 당뇨병을 예방하기 위한 방법 및 조성물 |
| KR20230077722A (ko) * | 2020-08-10 | 2023-06-01 | 지브이20 테라퓨틱스 엘엘씨 | Igsf8을 표적화하여 자가면역 질환 및 암을 치료하기 위한 조성물 및 방법 |
| MX2023013851A (es) | 2021-05-24 | 2023-12-08 | Provention Bio Inc | Metodos para el tratamiento de diabetes tipo 1. |
| WO2025251015A1 (en) * | 2024-05-30 | 2025-12-04 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Pan-gi norovirus monoclonal antibody and its use |
Family Cites Families (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US6673986B1 (en) | 1990-01-12 | 2004-01-06 | Abgenix, Inc. | Generation of xenogeneic antibodies |
| US6713610B1 (en) | 1990-01-12 | 2004-03-30 | Raju Kucherlapati | Human antibodies derived from immunized xenomice |
| US5877397A (en) | 1990-08-29 | 1999-03-02 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5874299A (en) | 1990-08-29 | 1999-02-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US6300129B1 (en) | 1990-08-29 | 2001-10-09 | Genpharm International | Transgenic non-human animals for producing heterologous antibodies |
| US6255458B1 (en) | 1990-08-29 | 2001-07-03 | Genpharm International | High affinity human antibodies and human antibodies against digoxin |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US6342220B1 (en) | 1997-08-25 | 2002-01-29 | Genentech, Inc. | Agonist antibodies |
| AU6366999A (en) | 1998-10-30 | 2000-05-22 | Takeda Chemical Industries Ltd. | Betacellulin protein-containing preparations |
| US6900292B2 (en) | 2001-08-17 | 2005-05-31 | Lee-Hwei K. Sun | Fc fusion proteins of human erythropoietin with increased biological activities |
| KR100976076B1 (ko) | 2003-05-22 | 2010-08-17 | 아보트 러보러터리즈 | 인다졸, 벤즈이속사졸 및 벤즈이소티아졸 키나제 억제제 |
| DK1678314T3 (da) | 2003-10-22 | 2012-12-03 | Keck Graduate Inst | Fremgangsmåde til syntetisering af heteromultimere polypeptider i gær ved anvendelse af en haploid parringsstrategi |
| TWI309240B (en) | 2004-09-17 | 2009-05-01 | Hoffmann La Roche | Anti-ox40l antibodies |
| WO2006076288A2 (en) | 2005-01-11 | 2006-07-20 | Five Prime Therapeutics, Inc. | Dna constructs for long-term expression of intravascularly injected naked dna |
| WO2006081430A2 (en) | 2005-01-27 | 2006-08-03 | Five Prime Therapeutics, Inc. | Leader sequences for directing secretion of polypeptides and methods for production thereof |
| JP5238936B2 (ja) | 2005-03-25 | 2013-07-17 | ジーアイティーアール，インク． | Ｇｉｔｒ結合分子およびその使用 |
| DK1879573T3 (da) | 2005-05-10 | 2013-02-25 | Incyte Corp | Modulatorer af indolamin 2,3-dioxygenase og fremgangsmåder til anvendelse deraf |
| KR101704734B1 (ko) | 2005-07-01 | 2017-02-09 | 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. | 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체 |
| ES2540561T3 (es) | 2005-12-20 | 2015-07-10 | Incyte Corporation | N-hidroxiamidinoheterociclos como moduladores de indolamina 2,3-dioxigenasa |
| CA2663057C (en) | 2006-09-19 | 2015-12-08 | Incyte Corporation | N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase |
| CL2007002650A1 (es) | 2006-09-19 | 2008-02-08 | Incyte Corp | Compuestos derivados de heterociclo n-hidroxiamino; composicion farmaceutica, util para tratar cancer, infecciones virales y desordenes neurodegenerativos entre otras. |
| EP1987839A1 (en) | 2007-04-30 | 2008-11-05 | I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale | Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease |
| PT2175884T (pt) | 2007-07-12 | 2016-09-21 | Gitr Inc | Terapias de combinação empregando moléculas de ligação a gitr |
| US7981415B2 (en) | 2007-09-07 | 2011-07-19 | Cisthera, Inc. | Humanized PAI-1 antibodies |
| EP2044949A1 (en) | 2007-10-05 | 2009-04-08 | Immutep | Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response |
| WO2009073620A2 (en) | 2007-11-30 | 2009-06-11 | Newlink Genetics | Ido inhibitors |
| AR072999A1 (es) | 2008-08-11 | 2010-10-06 | Medarex Inc | Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos |
| MX356367B (es) | 2008-12-09 | 2018-05-25 | Genentech Inc | Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t. |
| IN2015DN02826A (enExample) | 2009-09-03 | 2015-09-11 | Merck Sharp & Dohme | |
| WO2011130417A2 (en) * | 2010-04-15 | 2011-10-20 | Amgen Inc. | HUMAN FGF RECEPTOR AND β-KLOTHO BINDING PROTEINS |
| NZ729044A (en) | 2010-09-09 | 2020-07-31 | Pfizer | 4-1bb binding molecules |
| NO2694640T3 (enExample) | 2011-04-15 | 2018-03-17 | ||
| CA2833636A1 (en) | 2011-04-20 | 2012-10-26 | Amplimmune, Inc. | Antibodies and other molecules that bind b7-h1 and pd-1 |
| BR112014012819B1 (pt) | 2011-11-28 | 2022-08-16 | Merck Patent Gmbh | Anticorpo anti-pd-l1 ou fragmento de ligação ao antígeno do mesmo e composição |
| MX356337B (es) | 2011-12-15 | 2018-05-23 | Hoffmann La Roche | Anticuerpos contra csf-1r humano y sus usos. |
| MX2014008961A (es) | 2012-02-06 | 2014-10-14 | Genentech Inc | Composiciones y metodos para utilizar inhibidores de csf1r. |
| AR090263A1 (es) | 2012-03-08 | 2014-10-29 | Hoffmann La Roche | Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma |
| KR20150018533A (ko) | 2012-05-11 | 2015-02-23 | 파이브 프라임 테라퓨틱스, 인크. | 콜로니 자극 인자 1 수용체(csf1r)에 결속하는 항체들에 의한 질병 상태의 치료 방법 |
| AR091649A1 (es) | 2012-07-02 | 2015-02-18 | Bristol Myers Squibb Co | Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y sus usos |
| CN107759690A (zh) | 2012-08-31 | 2018-03-06 | 戊瑞治疗有限公司 | 用结合群落刺激因子1受体(csf1r)的抗体治疗病状的方法 |
| TW201605896A (zh) | 2013-08-30 | 2016-02-16 | 安美基股份有限公司 | Gitr抗原結合蛋白 |
| PT3370768T (pt) * | 2015-11-03 | 2022-04-21 | Janssen Biotech Inc | Anticorpos que se ligam especificamente ao pd-1 e seus usos |
| EP3401332A1 (en) * | 2017-05-08 | 2018-11-14 | MAB Discovery GmbH | Anti-il-1r3 antibodies for use in inflammatory conditions |
| BR112020007751A2 (pt) * | 2017-10-25 | 2020-10-20 | Acceleron Pharma Inc. | proteínas de ligação de alk7 e usos das mesmas |
| KR102163305B1 (ko) * | 2017-11-16 | 2020-10-08 | 오름테라퓨틱 주식회사 | 세포의 세포질에 침투하여 세포내 활성화된 Ras를 억제하는 항체 및 이의 용도 |
| TW202135861A (zh) * | 2019-12-25 | 2021-10-01 | 中國大陸商上海尋百會生物科技有限公司 | 藉由靶向igsf8以治療自體免疫疾病及癌症之組合物及方法 |
| KR20230077722A (ko) * | 2020-08-10 | 2023-06-01 | 지브이20 테라퓨틱스 엘엘씨 | Igsf8을 표적화하여 자가면역 질환 및 암을 치료하기 위한 조성물 및 방법 |
-
2021
- 2021-08-09 KR KR1020237008022A patent/KR20230077722A/ko active Pending
- 2021-08-09 EP EP21758306.1A patent/EP4192866A2/en active Pending
- 2021-08-09 MX MX2023001707A patent/MX2023001707A/es unknown
- 2021-08-09 CA CA3188996A patent/CA3188996A1/en active Pending
- 2021-08-09 CN CN202180069002.4A patent/CN116724051A/zh active Pending
- 2021-08-09 WO PCT/CN2021/111469 patent/WO2022033419A2/en not_active Ceased
- 2021-08-09 US US18/020,447 patent/US20230303695A1/en active Pending
- 2021-08-09 JP JP2023509663A patent/JP7832177B2/ja active Active
- 2021-08-09 IL IL300537A patent/IL300537A/en unknown
- 2021-08-09 AU AU2021325225A patent/AU2021325225A1/en active Pending
-
2022
- 2022-08-09 EP EP22856507.3A patent/EP4384551A4/en active Pending
- 2022-08-09 CN CN202280063856.6A patent/CN118660906A/zh active Pending
- 2022-08-09 IL IL310534A patent/IL310534A/en unknown
- 2022-08-09 AU AU2022325756A patent/AU2022325756A1/en active Pending
- 2022-08-09 WO PCT/US2022/039838 patent/WO2023018722A2/en not_active Ceased
- 2022-08-09 US US18/682,489 patent/US20240343798A1/en active Pending
- 2022-08-09 JP JP2024507076A patent/JP2024532726A/ja active Pending
- 2022-08-09 CA CA3228575A patent/CA3228575A1/en active Pending
- 2022-08-09 KR KR1020247007398A patent/KR20240044464A/ko active Pending
- 2022-08-09 MX MX2024001844A patent/MX2024001844A/es unknown
-
2026
- 2026-03-05 JP JP2026034828A patent/JP2026097939A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11942149B2 (en) | Bispecific binding molecules that are capable of binding CD137 and tumor antigens, and uses thereof | |
| Singh et al. | Monoclonal antibodies: a review | |
| US20250171558A1 (en) | HUMAN IgG Fc DOMAIN VARIANTS WITH IMPROVED EFFECTOR FUNCTION | |
| US20210371544A1 (en) | Low-viscosity antigen binding proteins and methods of making them | |
| US11119096B2 (en) | Universal assay for determining the quantity of therapeutic monoclonal antibodies and their corresponding anti-drug-antibodies in samples | |
| JP2024532726A5 (enExample) | ||
| AU2018246873A1 (en) | ErbB-2 and ErbB3 binding bispecific antibodies for use in the treatment f cells that have an NRG1 fusion gene | |
| US12098214B2 (en) | Combination therapies for treating cancer | |
| US12435155B2 (en) | CD137 binding molecules and uses thereof | |
| CN116724051A (zh) | 用于通过靶向igsf8来治疗自身免疫性疾病和癌症的组合物和方法 | |
| US20240307548A1 (en) | Enhanced targeting using antibody-oligonucleotide conjugates | |
| JP2024508886A5 (enExample) | ||
| CN115397851B (zh) | Cxcl10结合蛋白及其用途 | |
| EA046873B1 (ru) | Cd137-связывающие молекулы и варианты их применения | |
| OA19914A (en) | Human IgG Fc domain variants with improved effector function. |